603 related articles for article (PubMed ID: 33574818)
1. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
5. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
7. Immune-metabolic interactions in homeostasis and the progression to NASH.
Hoogerland JA; Staels B; Dombrowicz D
Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
[TBL] [Abstract][Full Text] [Related]
8. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease.
Arendt BM; Teterina A; Pettinelli P; Comelli EM; Ma DWL; Fung SK; McGilvray ID; Fischer SE; Allard JP
Nutrition; 2019 Jun; 62():100-107. PubMed ID: 30870804
[TBL] [Abstract][Full Text] [Related]
9. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
Front Immunol; 2020; 11():627424. PubMed ID: 33603757
[TBL] [Abstract][Full Text] [Related]
11. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.
Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A
Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074
[TBL] [Abstract][Full Text] [Related]
13. Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis.
Park A; Choi SJ; Park S; Kim SM; Lee HE; Joo M; Kim KK; Kim D; Chung DH; Im JB; Jung J; Shin SK; Oh BC; Choi C; Nam S; Lee DH
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563425
[TBL] [Abstract][Full Text] [Related]
14. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
16. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
18. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
Wang L; Liu XE; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
[TBL] [Abstract][Full Text] [Related]
20. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
